Bajaj Healthcare's Board has approved Q1 financial results.

Revenue from operations for the quarter stood at ₹148.84 Cr, with a Profit after Tax from continuing operations of ₹12.17 Cr.

The company recently completed a preferential issue, raising ₹152.26 Cr, primarily used for loan repayment.

An additional ₹52.71 Cr from warrants is due.

They also acquired Genrx Pharmaceuticals for ₹10.85 Cr in April, pending NCLT approval.

Discontinued operations resulted in a loss of ₹0.34 Cr for the quarter.